Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vesicoureteral reflux: a new treatment algorithm.

Arne Stenberg1, Terry W Hensle, Göran Läckgren

  • 1Section of Urology, University Children's Hospital, S-75185 Uppsala, Sweden.

Current Urology Reports
|June 27, 2002
PubMed
Summary

Dextranomer/hyaluronic acid (Dx/HA) copolymer offers a safe and effective endoscopic treatment for persistent vesicoureteral reflux (VUR) in children. This approach provides a single-procedure cure, avoiding long-term antibiotics or major surgery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lower urinary tract symptoms in adults treated for vesico-ureteral reflux in childhood, compared to healthy controls.

Scandinavian journal of urology·2026
Same author

PIC cystography in occult vesicoureteral reflux: A systematic review highlighting its utility in children with recurrent urinary tract infections and normal VCUG.

Journal of pediatric urology·2023
Same author

Controlled long term outcome of pyloromyotomy for pyloric stenosis: No long-term adverse effect.

Journal of pediatric surgery·2022
Same author

Non-Animal Stabilized Hyaluronic Acid/Dextranomer Gel (NASHA/Dx, Deflux) for Endoscopic Treatment of Vesicoureteral Reflux: What Have We Learned Over the Last 20 Years?

Urology·2021
Same author

Letter to the Editor re 'Update of the EAU/ESPU guidelines on urinary tract infections in children'.

Journal of pediatric urology·2021
Same author

Management of Vesicoureteral Reflux: What Have We Learned Over the Last 20 Years?

Frontiers in pediatrics·2021

Area of Science:

  • Pediatric Urology
  • Minimally Invasive Surgery
  • Biomaterials Science

Background:

  • Vesicoureteral reflux (VUR) affects 1% of children, increasing risks of pyelonephritis and kidney damage.
  • Current VUR treatments include antibiotic prophylaxis, open surgery, and endoscopic procedures.
  • Previous endoscopic materials raised safety and efficacy concerns.

Purpose of the Study:

  • To evaluate the safety and efficacy of dextranomer/hyaluronic acid (Dx/HA) copolymer for endoscopic VUR treatment.
  • To propose an updated treatment algorithm for persistent VUR in children.

Main Methods:

  • Review of emerging data on Dx/HA copolymer for VUR treatment.
  • Development of a new treatment algorithm based on established efficacy and safety.

Related Experiment Videos

Main Results:

  • Dx/HA copolymer demonstrates good long-term safety and efficacy in VUR treatment.
  • Endoscopic treatment with Dx/HA offers a single-procedure cure for VUR.

Conclusions:

  • Dx/HA copolymer is a viable alternative to prolonged antibiotic prophylaxis and open surgery for VUR.
  • A new algorithm recommends endoscopic treatment with Dx/HA for most children with persistent VUR.